PARENTERAL LOXAPINE IN SEVERELY DISTURBED SCHIZOPHRENIC-PATIENTS
- 1 January 1980
- journal article
- research article
- Vol. 41 (1) , 23-26
Abstract
Loxapine is a tricyclic antipsychotic drug of the dibenzoxapine class. An uncontrolled open trial of this compound was performed i.m. in 28 patients previously refractory to other neuroleptic drugs. These patients received 50-200 mg loxapine daily i.m. Clinical evaluation, BPRS [Brief Psychiatric Rating Scale], NOSIE [Nurses'' Observation Scale for Inpatient Evaluation] and biological evaluation were performed before and at the 8th day of the treatment. Global clinical evaluation and statistical analysis of BPRS showed the high efficacy of loxapine with a sedative effect during the initial phase and a disinhibiting and hallucinolytic character at a later stage. Tolerance to the preparation appeared good both locally and systematically with the possible exception of transient effects upon body temperature.This publication has 1 reference indexed in Scilit:
- Efficacy of loxapine in the treatment of paranoid schizophreniaPsychopharmacology, 1977